ENTEST BIOMEDICAL
Entest BioMedical, Inc. engages in the development and commercialization of immunotherapeutic therapies for the veterinary market. The company is developing ImenVax family of canine cancer vaccines, which include ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device that is inserted subcutaneously into the patient; ImenVax II that utilizes cell lines for sustained release of immunologically relevan... t cytokines for maximum anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses. It is also developing ENT-576 therapy for the treatment of chronic obstructive pulmonary disease. In addition, the company operates veterinary hospitals. Entest BioMedical, Inc. was founded in 2008 and is based in La Mesa, California.
ENTEST BIOMEDICAL
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2008-01-01
Address:
La Mesa, California, United States
Country:
United States
Website Url:
http://www.entb.net
Total Employee:
1+
Status:
Active
Contact:
1-619-644-3344
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Nginx DigiCert SSL CloudFront Google Adsense AdBlock Acceptable Ads Hetzner Google Adsense For Domains Thawte SSL
Current Employees Featured
Stock Details
Official Site Inspections
http://www.entb.net
- Host name: 96-126-111-165.ip.linodeusercontent.com
- IP address: 96.126.111.165
- Location: Newark United States
- Latitude: 40.739
- Longitude: -74.1697
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07175
More informations about "Entest BioMedical"
Enveric Biosciences
Mar 17, 2025 Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric …See details»
ENVB - Enveric Biosciences Inc. | Company Profile | OTC Markets
Mar 18, 2025 He has also served on the Board of Hope for New York, a 501 (c)3 organization dedicated to serving the poor in New York City from 2011 until 2014 where he was Treasurer …See details»
Enveric Biosciences, Inc. (ENVB) - Yahoo Finance
Find the latest Enveric Biosciences, Inc. (ENVB) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Enveric Biosciences (ENVB) Company Profile & Description
11 rows 4 days ago Company profile for Enveric Biosciences, Inc. (ENVB) stock, with a …See details»
Enveric Biosciences CEO Issues Letter to Shareholders
Feb 27, 2025 Enveric Biosciences (NASDAQ: ENVB) has announced strategic updates through a CEO letter to shareholders. The company has repositioned to focus on developing EB-003, their lead non-hallucinogenic neuroplastogenic …See details»
Enveric Biosciences Signs Out-Licensing Agreement with …
Nov 12, 2024 CAMBRIDGE, Mass. – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel …See details»
Enveric Biosciences - Crunchbase Company Profile & Funding
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines.See details»
Enveric Biosciences Announces Pricing of $5 Million …
CAMBRIDGE, Mass., January 31, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small ...See details»
ENVB | Enveric Biosciences Inc. Profile | MarketWatch
Enveric Biosciences Inc. Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance …See details»
Enveric Biosciences (ENVB) Stock Price, News & Analysis
Mar 21, 2025 Should You Buy or Sell Enveric Biosciences Stock? Get The Latest ENVB Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.See details»
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 ...
CAMBRIDGE, Mass., November 25, 2024--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of …See details»
Enveric Biosciences Reports Second Quarter 2024 Financial and …
Aug 12, 2024 Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of …See details»
Enveric Biosciences Advances Novel Anxiety Drug Development at …
Mar 17, 2025 Enveric Biosciences (NASDAQ: ENVB) announced its participation in BIO-Europe Spring®, taking place in Milan, Italy, March 17-19, 2025. The biotechnology company, focused …See details»
Enveric Biosciences Announces $5M Public Offering for Drug …
Jan 31, 2025 Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics, has announced the pricing of a $5 …See details»
Enveric Biosciences Prices Public Offering At $3.00/Shr
Jan 31, 2025 Cambridge, Massachusetts-based Enveric Biosciences, Inc. (ENVB), a biotechnology company focused on developing treatments for mental health disorders, has …See details»
Enveric Biosciences Signs Out-Licensing Agreement with …
CAMBRIDGE, Mass., November 12, 2024--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of …See details»
Enveric Biosciences Secures Patent for Novel CNS Compounds …
Feb 25, 2025 Enveric Biosciences (NASDAQ: ENVB) has secured U.S. Patent No. 12,195,439 for its new EVM401 Series of mescaline derivative compounds. The patent, issued on January …See details»
Joseph Tucker, PhD - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
Enveric Biosciences Receives Notice of Allowance for Lead Drug ...
Jan 30, 2025 Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of …See details»
CPECN Article
The GIC is committed to advancing the chemical industry towards a net-zero future and a circular economy. To learn more about the organization and its goals, Canadian Process Equipment & …See details»